Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/28957
Title: | Cost effectiveness of nifedipine compared with atosiban in the treatment of threatened preterm birth (APOSTEL III trial) | Authors: | Nijman, T. A. J. van Baaren, G. J. van Vliet, E. O. G. Kok, M. GYSELAERS, Wilfried Porath, M. M. Woiski, M. de Boer, M. A. Bloemenkamp, K. W. M. Sueters, M. Franx, A. Mol, B. W. J. Oudijk, M. A. |
Issue Date: | 2019 | Publisher: | WILEY | Source: | BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 126(7), p. 875-883 | Abstract: | Objective To assess the cost-effectiveness of treatment with nifedipine compared with atosiban in women with threatened preterm birth. Design An economic analysis alongside a randomised clinical trial (the APOSTEL III study). Setting Obstetric departments of 12 tertiary hospitals and seven secondary hospitals in the Netherlands and Belgium. Population Women with threatened preterm birth between 25 and 34 weeks of gestation, randomised for tocolysis with either nifedipine or atosiban. Methods We performed an economic analysis from a societal perspective. We estimated costs from randomisation until discharge. Analyses for singleton and multiple pregnancies were performed separately. The robustness of our findings was evaluated in sensitivity analyses. Main outcome measures Mean costs and differences were calculated per woman treated with nifedipine or atosiban. Health outcomes were expressed as the prevalence of a composite of adverse perinatal outcomes. Results Mean costs per patients were significantly lower in the nifedipine group [singleton pregnancies: euro34,897 versus euro43,376, mean difference (MD) -euro8479 [95% confidence interval (CI) -euro14,327 to -euro2016)]; multiple pregnancies: euro90,248 versus euro102,292, MD -euro12,044 (95% CI -euro21,607 to euro -1671). There was a non-significantly higher death rate in the nifedipine group. The difference in costs was mainly driven by a lower neonatal intensive care unit admission (NICU) rate in the nifedipine group. Conclusion Treatment with nifedipine in women with threatened preterm birth results in lower costs when compared with treatment with atosiban. However, the safety of nifedipine warrants further investigation. Tweetable abstract In women with threatened preterm birth, tocolysis using nifedipine results in lower costs when compared with atosiban. | Notes: | [Nijman, T. A. J.; van Vliet, E. O. G.; Bloemenkamp, K. W. M.; Franx, A.] Univ Med Ctr Utrecht, Div Woman & Baby, Birth Ctr, Utrecht, Netherlands. [Nijman, T. A. J.; Sueters, M.] Leiden Univ, Med Ctr, Dept Obstet & Gynaecol, Leiden, Netherlands. [van Baaren, G. J.; Kok, M.; Oudijk, M. A.] Univ Amsterdam, Amsterdam UMC, Dept Obstet & Gynecol, Amsterdam, Netherlands. [Gyselaers, W.] Ziekenhuis Oost Limburg, Dept Obstet & Gynecol, Genk, Belgium. [Gyselaers, W.] Hasselt Univ, Dept Physiol, Diepenbeek, Belgium. [Porath, M. M.] Maxima Med Ctr, Dept Obstet & Gynaecol, Veldhoven, Belgium. [Woiski, M.] Univ Med Ctr Nijmegen, Dept Obstet & Gynaecol, Nijmegen, Netherlands. [de Boer, M. A.] Vrije Univ, Amsterdam UMC, Dept Obstet & Gynaecol, Amsterdam, Netherlands. [Mol, B. W. J.] Monash Univ, Sch Med, Dept Obstet & Gynecol, Melbourne, Vic, Australia. | Keywords: | Atosiban; cost-effectiveness; nifedipine; perinatal outcomes; preterm birth; tocolysis | Document URI: | http://hdl.handle.net/1942/28957 | ISSN: | 1470-0328 | e-ISSN: | 1471-0528 | DOI: | 10.1111/1471-0528.15625 | ISI #: | 000467586100013 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2020 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
nijman 1.pdf Restricted Access | Published version | 425.79 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
1
checked on Sep 5, 2020
WEB OF SCIENCETM
Citations
2
checked on Oct 18, 2024
Page view(s)
102
checked on Sep 7, 2022
Download(s)
128
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.